Finerenone Prescriptions in the United States (2021–2024) by Physician Specialty: Analysis of Use and Potential in the Cardiovascular‐Kidney‐Metabolic Space Authors: Yara Jelwan, Tianyu Cao, Zhiqi Yao, Semenawit Burka, John Erhabor, Phillip Berning, Omar Dzaye, Michael Blaha Published: 2026 ABSTRACT AbstractBackgroundFinerenone, a nonsteroidal mineralocorticoid receptor antagonist, has demonstrated greater receptor selectivity and fewer adverse effects compared with older mineralocorticoid receptor antagonists. Clinical trials support its efficacy in reducing kidney disease progression, cardiovascular events, and heart failure outcomes across various patient populations; however, anecdotally, the drug appears infrequently used in clinical practice.MethodsA serial, cross‐sectional analysis of IQVIA's National Prescription Audit, which covers >70% of US outpatient prescription activity, was conducted from July 2021 to December 2024 to examine finerenone prescribing trends, focusing on cardiologists and nephrologists. For added context, prescription rates of finerenone were compared with those of 2 other medications with related mechanisms or indications commonly used in cardiovascular‐kidney‐metabolic syndrome, spironolactone and empagliflozin. Prescribing trends were correlated with total search activity using Google Trends.ResultsWe found that finerenone was prescribed at a rate of 30 180 prescriptions/month in December 2022, increasing to 45 420 prescriptions/month in December 2023, and to 60 756 prescriptions/month in December 2024. This modest increase correlated with changes in Google search activity, with mild inflections after the release of major clinical trial data. The ratio of total prescriptions from nephrologists (15.81 prescriptions per nephrologist)/cardiologists (0.70 prescriptions per cardiologist) in 2024 was ≈23:1. The proportion of finerenone prescriptions to other cardiovascular‐kidney‐metabolic therapies remained low, with finerenone prescriptions numerically representing 3.0% of empagliflozin prescriptions and 2.6% of spironolactone prescriptions in 2024.ConclusionsThe adoption of finerenone has been modest, especially among cardiologists compared with nephrologists, and lags behind other cardiovascular‐kidney‐metabolic therapies. However, recent trends show an upward shift in its use that correlates with public interest related to clinical trial results.Keywords: cardiometabolic health, cardiovascular‐kidney‐metabolic syndrome, finerenoneSubject Categories: Cardiovascular Disease, Epidemiology Nonstandard Abbreviations and Acronyms cardiovascular‐kidney‐metabolic Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure heart failure with preserved ejection fraction mineralocorticoid receptor antagonist sodium‐glucose cotransporter 2 inhibitor type 2 diabetes Clinical Perspective What Is New? National prescription data demonstrate that finerenone uptake in the United States has increased since approval but remains substantially lower among cardiologists compared with nephrologists. National prescription data demonstrate that finerenone uptake in the United States has increased since approval but remains substantially lower among cardiologists compared with nephrologists. When standardized per prescriber, cardiologists contribute a smaller proportion of finerenone prescriptions despite overlapping indications within cardiometabolic kidney disease. When standardized per prescriber, cardiologists contribute a smaller proportion of finerenone prescriptions despite overlapping indications within cardiometabolic kidney disease. What Are the Clinical Implications? These findings highlight an opportunity to further integrate finerenone into cardiology‐led cardiovascular‐kidney‐metabolic management pathways, alongside other cardiovascular‐kidney‐metabolic therapies, to advance comprehensive risk reduction. These findings highlight an opportunity to further integrate finerenone into cardiology‐led cardiovascular‐kidney‐metabolic management pathways, alongside other cardiovascular‐kidney‐metabolic therapies, to advance comprehensive risk reduction. Cardiovascular disease, chronic kidney disease (CKD), and metabolic conditions share common pathophysiological pathways and frequently coincide in the same population. 1 , 2 This overlap, known as cardiovascular‐kidney‐metabolic (CKM) syndrome, has been recently defined by the American Heart Association as a systemic disorder involving interactions between metabolic risk factors, chronic kidney injury, and the cardiovascular system. 3 CKM has been recognized as a major determinant of premature morbidity and mortality; it affects individuals at risk for cardiovascular disease, as well as those with existing cardiovascular disease, and is worsened by CKD and metabolic risk factors. 4 Several targeted therapies have emerged, simultaneously addressing and improving those interconnected disease states in CKM syndrome. 4 Among these, mineralocorticoid receptor antagonists (MRAs) are a class of medications that have long been used to manage multiple components of that syndrome. Mineralocorticoid receptor activation in the distal nephron enhances sodium reabsorption and potassium excretion, leading to volume expansion, hypertension, and electrolyte imbalance. 5 In nonepithelial tissues, such as the heart and interstitium, inappropriate or excessive mineralocorticoid receptor activation induces proinflammatory and profibrotic gene expression, mediated by oxidative stress, transforming growth factor‐β, and connective tissue growth factor. 6 , 7 These pathways promote tissue remodeling, fibrosis, and organ dysfunction, contributing to the progression of CKD and cardiovascular disease. 8 By blocking the binding of aldosterone to the MR, MRAs reduce these pathologic downstream effects, thus reducing fluid retention, lowering blood pressure, and protecting against organ damage, particularly in conditions like CKD and heart failure (HF). 5 Historically, steroidal MRAs, such as spironolactone and eplerenone, have been used in the management of HF and hypertension. Other steroidal MRAs with substantially lower affinity for androgen and progesterone receptors, such as eplerenone and, in some countries, canrenone, are also used in clinical practice for similar indications, albeit with lower mineralocorticoid receptor potency compared with spironolactone. 9 , 10 , 11 More recently, finerenone, a nonsteroidal MRA, has demonstrated greater selectivity and fewer adverse effects compared with older MRAs. It also had more potent anti‐inflammatory and antifibrotic effects than steroidal mineralocorticoid receptor antagonists (namely, spironolactone and eplerenone) in preclinical models, with multiple clinical trials supporting its use in various conditions across the CKM spectrum. 5 For example, the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO‐DKD) trial demonstrated that finerenone significantly reduced the progression of kidney disease in patients with CKD and type 2 diabetes (T2D). 12 Shortly after, in 2021, the FIGARO‐DKD (Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease) trial showed that finerenone was associated with decreased cardiovascular events in a similar study population. 13 In 2024, the FINEARTS‐HF (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure) showed that finerenone reduced the risk of the primary composite outcome of cardiovascular death and total HF events in patients with heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction (HFpEF). 14 Finerenone has received varying levels of recommendation in both US and European clinical practice guidelines. The US Kidney Disease: Improving Global Outcomes 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease gives finerenone a class 2A recommendation for use in patients with T2D, an estimated glomerular filtration rate ≥25 mL/min per 1.73 m2, normal serum potassium concentration, and albuminuria (≥30 mg/g or ≥3 mg/mmol), despite the maximum tolerated dose of a renin‐angiotensin system inhibitor. 15 This contrasts with the class 1A recommendation for sodium‐glucose cotransporter 2 inhibitors (SGLT2is) for a similar patient population. In Europe, finerenone has been given a class 1 recommendation in the 2023 European Society of Cardiology Guidelines for the Management of Cardiovascular Disease in Patients With Diabetes, 16 highlighting its role in reducing both cardiovascular and kidney failure risks when added to standard care. Real‐world data consistently show that MRAs remain substantially underused across clinical practice, often because of concerns about hyperkalemia and monitoring burden, with similar patterns reported in CKD and cardiometabolic populations, suggesting that similar barriers may also affect adoption of finerenone. 17 , 18 However, despite its apparent efficacy and support from various societies, anecdotal reports suggest low use of finerenone by different physician specialties, 19 particularly cardiologists. This study aims to quantify recent trends in patterns of prescription of finerenone in the United States, with an emphasis on different specialties and a comparison to other therapies targeting the CKM system. METHODS This study was exempt from institutional review board oversight because it involved the analysis of deidentified, aggregated prescription data, with no interaction with human subjects and no access to identifiable private information. The data that support the findings of this study are available from the corresponding author on reasonable request. We performed a serial, cross‐sectional analysis of IQVIA's National Prescription Audit. The National Prescription Audit has been used in cardiovascular‐related studies to analyze prescription trends and patterns in clinical practice. 20 , 21 , 22 The National Prescription Audit represents and captures >70% of all prescription activity in the United States, including Alaska and Hawaii, and covers all products, classes, and manufacturers. 23 The National Prescription Audit then provides dispensing estimates based on a sample of ≈90% of all retail prescriptions dispensed in the United States, including 90% of retail pharmacies, 80% of nursing home pharmacies, and 70% of mail‐service pharmacies. Data from IQVIA's database were used to capture total finerenone prescribing trends across various medical specialties from the Association of American Medical Colleges and then specific trends for the cardiology and nephrology specialties. Finerenone in this analysis is referred to as the total aggregate of all relevant products, including the chemical name finerenone and brand name Kerendia. To compare prescription rates between cardiologists, nephrologists, and the total number of provider prescriptions, we graphed the total annual prescriptions of finerenone by each specialty from July 2021 to December 2024, in comparison to the total annual prescriptions by all providers. To standardize the comparison per individual prescriber, we then divided the estimated yearly prescription volume of each specialty by the total number of cardiologists and nephrologists in the United States, respectively, obtaining the average annual prescriptions per physician for each specialty. We obtained the number of physicians in different specialties from the Association of American Medical Colleges US Physician Workforce Data Report in 2023, which draws from the American Medical Association Physician Masterfile. 24 This approach allowed us to assess the most recent relative contribution of each specialty to finerenone prescribing. We also directly compared finerenone prescription with that of spironolactone, the most used MRA, and empagliflozin, the first SGLT2i on the market. Both are older medications that are established in CKM syndrome with similar indications. Given that finerenone is a new drug on the market, we chose to compute the ratio of finerenone prescriptions/these other CKM therapies on a year‐by‐year basis to properly account for changing trends over time. For spironolactone and empagliflozin, national prescription data from 2019 and 2020 were included to provide baseline prescribing patterns before finerenone was introduced. Finally, we compared total prescriptions of finerenone, spironolactone, and empagliflozin by provider specialty. Online search data for the United States were retrieved for the period between July 2021 and December 2024 using the Google Health Trends Application Programming Interface, as described in previous studies. 22 Google Health Trends captures a sample of all public Google searches, including data from both signed‐out and some signed‐in users. Although it excludes infrequent searches and duplicate queries from the same user within a short time frame, Google Health Trends cannot entirely exclude the possibility that the same user may use multiple devices. Online search data were extracted from Google Health Trends as query fractions per 10 million searches, representing ≈89% of all online searches for all individual drug brand names and chemical names. Statistical Analysis We used descriptive statistics to perform our analyses. We evaluated >197 million estimated prescriptions for finerenone, spironolactone, and empagliflozin, assessing monthly and yearly changes in prescription volumes. To compare relative use across the 3 drugs, we calculated the proportion of total prescriptions represented by each drug. We also examined annual prescriptions dispensed per physician within cardiology and nephrology specialties. These outcomes were visualized over time to identify notable trends and inflection points, which we then contextualized by overlaying key clinical trial publications and US Food and Drug Administration drug label expansions. All analyses were performed using R and Microsoft Excel. RESULTS Monthly Prescription Trends in the United States and Correlation With Google Search Activity Between July 2021 and November 2024, the total monthly prescription rates of finerenone in the United States exhibited a consistent upward trend (Figure 1). Initially, prescription numbers started at 568 in June 2021, within the first year of the introduction of finerenone/Kerendia to the market. This increase continued through 2023 and 2024, reaching peak levels by the latest recorded data in December 2024. In parallel, online search interest for both “finerenone” and its brand name “Kerendia” followed a similar trajectory, with fluctuations corresponding to specific time points: the release of the 2022 Kidney Disease: Improving Global Outcomes guidelines in November 2022 and the publication of the results of the FINEARTS‐HF in September 2024 (Figure 1, Figure S1). Monthly prescription trends for finerenone in the United States across all specialties and correlation with Google search activity. Monthly prescription volumes (blue bars; left y axis) are plotted alongside Google search counts for “finerenone” and “Kerendia” (orange line; right y axis) from June 2021 through December 2024. Vertical arrows indicate the timing of key events, including FDA approval, publication of the FIGARO‐DKD trial, release of the 2022 KDIGO guidelines, and the FINEARTS‐HF. FDA indicates US Food and Drug Administration; FIGARO‐DKD, Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease; FINEARTS‐HF, Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure; and KDIGO, Kidney Disease: Improving Global Outcomes. Annual Prescription Volumes Overall and by Specialties From 2021 to 2024, the total number of annual finerenone prescriptions increased from 13 853 to 636 668 (Figure 2A). Between 2021 and 2024, annual prescriptions for finerenone increased across both cardiology and nephrology specialties (Figure 2A). In 2021, nephrologists accounted for 4269 prescriptions and cardiologists for 516. By 2024, nephrology prescriptions had increased to 195 372, whereas cardiology prescriptions reached 16 016. The proportion of total prescriptions attributed to nephrology was 30.8% (4269/13 853) in 2021, 31.2% (68 326/218 799) in 2022, 30.5% (145 822/477 207) in 2023, and 30.7% (195 372/636 668) in 2024. The absolute number of prescriptions from cardiologists also increased each year, with the largest year‐over‐year change occurring between 2021 and 2022 (6412 prescriptions). Over the same period, the proportion of prescriptions attributed to cardiologists relative to the total amount of prescriptions was 3.7% (516/13 853) in 2021, 3.2% (6928/218 799) in 2022, 2.6% (12 555/477 207) in 2023, and 2.5% (16 016/636 668) in 2024. Although both specialties showed year‐over‐year increases in the absolute number of prescriptions, the relative proportion of total prescriptions remained higher and more stable for nephrologists compared with cardiologists over the study period. Annual prescriptions of finerenone by specialty in the United States. A, Total annual finerenone prescriptions (blue) and prescriptions stratified by nephrology (orange) and cardiology (red) from 2021 through 2024. B, Annual prescriptions per physician in nephrology and cardiology over the same period. Data demonstrate a greater absolute and per‐physician uptake among nephrologists compared with cardiologists. Using 2023 estimates of active physicians from the Association of American Medical Colleges Physician Workforce Data Dashboard, the number of finerenone prescriptions per physician increased each year for both specialties. According to the 2023 US Physician Workforce Data Dashboard, there were 22 843 physicians specializing in cardiovascular disease and 12 360 physicians specializing in nephrology in the United States and its territories. Among cardiologists, yearly prescriptions per physician were ≈0.02 in 2021, 0.30 in 2022, 0.55 in 2023, and 0.70 in 2024 (Figure 2B). Among nephrologists, the corresponding values were ≈0.35 in 2021, 1.12 in 2022, 11.80 in 2023, and 15.81 in 2024. Comparison to the Prescriptions of Spironolactone and Empagliflozin Finerenone yearly prescriptions increased from 13 853 in 2021 to 636 668 in 2024, whereas spironolactone prescriptions increased from 19 458 298 to 24 328 627 over the same period (Table). The proportion of finerenone to spironolactone prescriptions increased from 0.07% in 2021 to 2.62% in 2024. Year over year, finerenone prescriptions increased by 33% between 2023 and 2024 (from 477 207 to 636 668), whereas spironolactone prescriptions increased by 7% (from 22 644 106 to 24 328 627). Over the full study period (2019–2024), a total of 1 346 527 prescriptions were written for finerenone and 123 416 916 prescriptions were written for spironolactone. Table 1Annual Prescription Counts of MRA Drugs and Comparative Use of Finerenone, From 2019 to 2024Variable201920202021202220232024Total from 2019 to 2024MRA drugs, prescription countsFinerenone0013 853218 799 (1479)477 207 (118)636 668 (33)1 346 527 (9620)Empagliflozin5 430 9087 336 693 (35)9 537 827 (30)12 844 284 (35)16 785 904 (31)21 189 582 (26)73 125 198 (290)Spironolactone17 656 90218 560 062 (5)19 458 298 (5)20 768 921 (7)22 644 106 (9)24 328 627 (7)123 416 916 (38)Finerenone prescriptions relative to other drugsvs Empagliflozin, %000.151.702.843.001.84vs Spironolactone, %000.071.052.112.621.09Values represent absolute prescription counts, with percentages in parentheses indicating year‐over‐year change. The right‐most column shows cumulative prescriptions across the 6‐year period and the overall percentage change from 2019 to 2024. The lower section reports finerenone prescriptions as a percentage of empagliflozin and spironolactone use.MRA indicates mineralocorticoid receptor antagonist. Annual Prescription Counts of MRA Drugs and Comparative Use of Finerenone, From 2019 to 2024 Values represent absolute prescription counts, with percentages in parentheses indicating year‐over‐year change. The right‐most column shows cumulative prescriptions across the 6‐year period and the overall percentage change from 2019 to 2024. The lower section reports finerenone prescriptions as a percentage of empagliflozin and spironolactone use. MRA indicates mineralocorticoid receptor antagonist. Empagliflozin prescriptions increased from 9 537 827 in 2021 to 21 189 582 in 2024 (Table). In comparison, finerenone prescriptions increased from 13 853 to 636 668 during the same period. Finerenone prescription volume was equivalent to 0.15% (13 853/9 537 827) of empagliflozin prescriptions in 2021 and 3.00% (636 668/21 189 582) in 2024. Between 2023 and 2024, empagliflozin prescriptions increased by 26% (from 16 785 904 to 21 189 582), whereas finerenone prescriptions increased by 33%. Across the full study period, there were 73 125 198 prescriptions for empagliflozin and 1 346 527 prescriptions for finerenone. From January 2019 to July 2024, using a denominator of total prescriptions of finerenone+spironolactone+empagliflozin, the proportion of total prescriptions represented by spironolactone decreased steadily, from >75% in early 2019 to just above 50% by mid‐2024 (Figure 3). During the same period, empagliflozin's share increased consistently, increasing from ≈25% in 2019 to nearly 45% by mid‐2024. Finerenone, introduced in 2021, accounted for a small but gradually increasing share of prescriptions, reaching 1.5% by 2024. Relative prescription share of finerenone, spironolactone, and empagliflozin in the United States, from 2019 to 2024. Monthly prescription proportions of spironolactone (blue), empagliflozin (red), and finerenone (dark blue) are shown from January 2019 through December 2024. Key FDA approval dates are indicated by arrows. The inset pie chart displays prescription share at the end of the study period (December 2024), with spironolactone accounting for 51.4%, empagliflozin accounting for 47.1%, and finerenone accounting for 1.5% of total prescriptions. FDA indicates US Food and Drug Administration. DISCUSSION Despite strong evidence supporting the cardiorenal benefits of finerenone in patients with CKD and T2D, use of this therapy remains limited relative to other agents with overlapping indications. In this study, we analyzed a national audit of retail prescriptions to evaluate the uptake of finerenone by specialty since its market introduction in 2021. Although total finerenone use increased substantially between 2021 and 2024, cardiologists accounted for a small proportion of overall prescriptions each year, with prescribing per cardiologist remaining markedly lower than that of nephrologists. In 2024, finerenone prescriptions per nephrologist were >20 times higher than those per cardiologist. These findings parallel prior analyses of other cardiometabolic therapies, such as SGLT2i and glucagon‐like peptide‐1 receptor agonists, which also demonstrated low initial rates of uptake by cardiologists, despite strong clinical trial evidence and formal endorsement in guidelines. 21 Possible Influence of Key Events on Finerenone Uptake The observed trajectory of finerenone prescriptions over time may have been influenced by the timing of key clinical trial publications and regulatory approvals. Initial uptake followed the publication of the FIDELIO‐DKD (Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease) trial in late 2020 and the subsequent US Food and Drug Administration approval for treatment of CKD associated with T2D in July 2021. A second inflection point occurred after the publication of the FIGARO‐DKD trial in 2021, which expanded the evidence base to a broader population with earlier‐stage CKD. Prescription volumes continued to increase steadily through 2023 and 2024, with an additional increase following the presentation of the FINEARTS‐HF in late 2024, which evaluated finerenone in patients with HFpEF. The impact of the HFpEF indication will require a full evaluation in a future dedicated analysis using, for example, 2025 and 2026 data. Despite these key milestones, search interest in finerenone, as assessed by Google Trends data, remained consistently lower than that of other medications in the same therapeutic space. 16 The volume of online searches for “finerenone” and the brand name “Kerendia” showed substantial peaks coinciding with trial publications or US Food and Drug Administration approvals, demonstrating a modest increase in public interest following its market introduction. Monthly prescription data show a steady, linear growth pattern over time without abrupt surges, suggesting that dissemination of trial results and regulatory events may have contributed incrementally, but modestly, to prescriber behavior. Barriers to Broader Adoption Several factors may contribute to the relatively modest uptake of finerenone, particularly among cardiologists. Although major trials have established its efficacy in reducing cardiorenal risk in patients with CKD and T2D, US clinical guidelines have not yet uniformly endorsed its use across specialties. The Kidney Disease: Improving Global Outcomes guidelines provide a class 2A recommendation for finerenone for CKD and T2D indication, 14 but US‐based cardiology guidelines have only recently begun to reflect its potential role. In contrast, the European Society of Cardiology has assigned finerenone a class 1A recommendation for CKD in patients with T2D, 15 reflecting a higher degree of endorsement compared with the United States. Familiarity and comfort with older MRAs, specifically spironolactone, may also influence prescribing behaviors. Spironolactone remains widely used because of its longstanding clinical role, low cost, and broad guideline inclusion across populations with heart failure and CKD. In contrast, finerenone, as a newer branded therapy, may face additional barriers related to higher cost, insurance coverage restrictions, and prior authorization requirements compared with generic steroidal MRAs, such as spironolactone, eplerenone, and canrenone, which could further limit its uptake in routine practice. Although finerenone offers a more selective pharmacologic profile and potentially lower risk of hyperkalemia, its newer status and lack of head‐to‐head trials with other MRAs may contribute to clinical inertia. Similarly, when compared with SGLT2is, recently introduced agents with broader indications, stronger class 1 guideline recommendations, and earlier market entry, finerenone has seen lower adoption, despite overlapping therapeutic goals. In 2024, for example, finerenone prescriptions totaled <3% of those for empagliflozin. Adoption may be slowed by uncertainty about which specialty should initiate finerenone, cardiology, nephrology, or endocrinology, given its positioning at the intersection of CKD, diabetes, and cardiovascular risk. Unlike finerenone, SGLT2is rapidly gained traction among cardiologists because early landmark trials demonstrated significant cardiovascular and heart failure benefits, likely creating strong specialty familiarity and accelerating adoption across the cardiovascular specialty spectrum. Structural factors, like cost and insurance coverage, also play a role. Like other newly approved therapies, finerenone may face coverage restrictions or require prior authorization, which can delay initiation. 25 Additionally, concerns about hyperkalemia and the need for ongoing laboratory monitoring may reduce enthusiasm among clinicians or patients, even when risks are relatively low. 26 Another factor for decreased use of finerenone might be because of the previous lack of data for use in conjunction with SGLT2is. Moreover, a multipillar approach to CKM had not been established until recently. In a CKM space increasingly crowded with effective options for therapy, physicians appear to have prioritized agents they were already familiar with. New guidelines emphasizing a multipillar approach to both CKD and HFpEF will likely influence future finerenone prescribing. Together, these factors highlight a persistent implementation gap between evidence generation and clinical practice. Targeted efforts to address specialty‐specific barriers, through education, updated guidelines, and coordinated care models, may be necessary to fully realize the benefits of finerenone in appropriate patient populations. These findings are likely generalizable to US outpatient clinical practice, given the broad national coverage of the IQVIA National Prescription Audit; however, extrapolation to non‐US health systems or to individual patient‐level prescribing decisions should be made with caution. There are a few limitations to this study. Foremost, our data run only through 2024, so it should not be interpreted as a thorough evaluation of the effects of the new HFpEF indication. Our data reflect dispensed prescriptions and, therefore, cannot capture attempts to prescribe finerenone that were denied by insurance or did not meet preauthorization requirements. Advanced practice providers remain difficult to categorize using these data sets, as the setting of their practice (primary care versus cardiology versus nephrology, for example) is not reflected in the data set. Finally, the data set does not include information on patient sex, comorbidities, or other clinical characteristics, which limits the ability to assess sex‐specific patterns or determine whether prescribing varies according to disease severity or risk profile. Additionally, the data set does not provide information on finerenone dose or measures of kidney function, such as estimated glomerular filtration rate or albuminuria, preventing analysis of dosing appropriateness or evaluation of whether changes in prescription patterns reflect shifts in underlying renal disease severity. To help close this gap in adoption, several practical steps may be useful. Increasing familiarity with finerenone through focused education on when and how to use it in CKM may help cardiologists feel more comfortable prescribing it. Clearer shared‐care pathways between cardiology, nephrology, and endocrinology could also reduce uncertainty about who should initiate therapy. In addition, incorporating CKM decision‐support prompts into electronic health records and streamlining insurance authorization may make it easier to start treatment when appropriate. CONCLUSIONS In conclusion, although finerenone has shown great potential in the CKM space, its adoption has been slow despite its inclusion in guidelines, and this appears to be reflected in Google search data. The rate of adoption is particularly slower among cardiologists compared with nephrologists, and its use remains limited when compared with other CKM therapies, like spironolactone and SGLT2is. To improve evidence‐based integration into clinical practice, more education and updated guidelines may be needed to better inform health care providers on finerenone's potential efficacy and appropriate use. Future analyses will be needed, using future prescribing data to study the effect of the new HFpEF indication. Sources of Funding No external funding was received for this work. Disclosures Dr Blaha has received research grants or contracts from the NIH, the U.S. Food and Drug Administration, the American Heart Association, Novo Nordisk, and Bayer; has received consulting fees from Scene Health and Autonomy Bio; has received honoraria for lectures and legal testimony from Novo Nordisk; and has served on data and safety monitoring boards or advisory boards for Novartis, Novo Nordisk, Bayer, Eli Lilly, Astra‐Zeneca, Boehringer Ingelheim, NewAmsterdam Pharma, Agepha Pharma US, Idorsia, Genentech, and Merck. Supporting information Figure S1 Acknowledgments The authors thank all colleagues who provided input and support. This manuscript was sent to Tazeen H. Jafar, MD, MPH, Associate Editor, for review by expert referees, editorial decision, and final disposition. Preprint posted on MedRxiv, October 5, 2025. https://doi.org/10.1101/2025.10.02.25337213. Supplemental Material is available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.125.046837 For Sources of Funding and Disclosures, see page 9. References Associated Data Supplementary Materials Figure S1